• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[实验性神经白血病的形态发生]

[Morphogenesis of experimental neuroleukemia].

作者信息

Petrov S A

出版信息

Arkh Patol. 1994 Mar-Apr;56(2):25-7.

PMID:8037587
Abstract

22 mice with L-1210 leukemia treated with quinoline dibromide were studied histologically. Two ways of the development of leptomeningeal infiltrates in the brain are established. The first is due to the growth of uninhibited by treatment bone-marrow leukemic infiltrates (LI) of the skull, while the second-when the above infiltrates are suppressed-due to the proliferation of leukemic cells penetrating from the dura mater to the leptomeninges protected by the hematoencephalic barrier from the effect of anticancer drugs. when the recurrence of leukemia occurs the growth of bone-marrow LI continues resulting in the additional migration of leukemic cells to the leptomeninges. These ways of the leptomeninx LI formation should be taken into consideration in the leukemia treatment.

摘要

对22只接受二溴喹啉治疗的L - 1210白血病小鼠进行了组织学研究。确定了白血病细胞在脑软脑膜浸润发展的两种方式。第一种是由于颅骨骨髓白血病浸润(LI)不受治疗抑制地生长,而第二种是当上述浸润被抑制时,由于白血病细胞从硬脑膜增殖穿透到受血脑屏障保护免受抗癌药物影响的软脑膜。当白血病复发时,骨髓LI继续生长,导致白血病细胞向软脑膜额外迁移。在白血病治疗中应考虑软脑膜LI形成的这些方式。

相似文献

1
[Morphogenesis of experimental neuroleukemia].[实验性神经白血病的形态发生]
Arkh Patol. 1994 Mar-Apr;56(2):25-7.
2
[Initial morphological manifestations in experimental neuroleukemia].[实验性神经白血病的初始形态学表现]
Eksp Onkol. 1990;12(1):31-4.
3
[Neuroleukemia in mice with leukemia L1210 treated with methotrexate].[用甲氨蝶呤治疗白血病L1210小鼠的神经白血病]
Gematol Transfuziol. 1989 Nov;34(11):46-50.
4
Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease.
J Natl Cancer Inst. 1985 May;74(5):1071-7.
5
[Cellular mechanism of the antileukemic action of quinoline dibromide].[二溴喹啉抗白血病作用的细胞机制]
Biull Eksp Biol Med. 1984 Jul;98(7):59-61.
6
[Morphogenesis of neuroleukemia].[神经白血病的形态发生]
Arkh Patol. 1982;44(7):52-8.
7
[Development of leukemia L-1210 after treatment with the methionine synthetase inhibitor quinoline dibromide].[用甲硫氨酸合成酶抑制剂二溴喹啉治疗后白血病L - 1210的发展]
Probl Gematol Pereliv Krovi. 1982 Jul;27(7):27-31.
8
Electronic volume analysis of L1210 chemotherapy.L1210化疗的电子体积分析
Cancer Res. 1976 Dec;36(12):4434-8.
9
Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Acta Pharmacol Sin. 2002 Oct;23(10):946-51.
10
The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors.
Cancer Res. 1973 Apr;33(4):895-901.